Core Viewpoint - Viatris (VTRS) is set to report its first-quarter 2025 results on May 8, 2025, with revenue estimates at $3.24 billion and earnings at $0.50 per share [1] Group 1: Revenue Performance by Segment - Growth in Developed Markets is expected to be driven by strong new product performance and generics, with revenue estimates at $1.9 billion [2][3] - Emerging Markets are likely to see growth from the expansion of the cardiovascular portfolio in Latin America and key markets like Turkey, India, and Brazil, with revenue estimates at $480 million [4] - Sales in JANZ (Japan, Australia, and New Zealand) are anticipated to be negatively impacted by government price regulations, with revenue estimates at $309 million [5] - Greater China may experience revenue growth due to demand for chronic disease management products, with estimates at $553 million [6] Group 2: Brand and Generic Performance - The brand business constitutes the majority of Viatris' portfolio, benefiting from cardiovascular portfolio expansion in Latin America and strong growth in Europe and Greater China [7] - Operating expenses are expected to rise due to investments in new product launches and R&D progress [7] Group 3: Stock Performance and Earnings History - Viatris' shares have declined by 31.2% over the past year, contrasting with a 1% decline in the industry [8] - The company has a mixed earnings surprise history, beating estimates in two of the last four quarters and missing in the other two, with an average surprise of 1.26% [9] Group 4: Earnings Prediction Model - The current model does not predict an earnings beat for Viatris, as it has a Zacks Rank of 4 (Sell) despite an Earnings ESP of +3.31% [10][11]